Navigation Links
2 new compounds show promise for eliminating breast cancer tumors
Date:11/19/2008

Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.

Associate Professor James Turkson's compounds disrupt the formation and spread of breast cancer tumors in tests on mice. The compounds, S3I-201 and S3I-M2001, break up a cancer-causing protein called STAT3, and researchers have observed no negative side effects so far.

"The compounds are very promising," Turkson said. "They've worked very well in mice, and now we're looking for partners to help us take these compounds to the next level of trials."

Turkson's research has been published in the academic journals Proceedings of the National Academy of Sciences and ACS Chemical Biology, and he has obtained patents for both compounds.

Turkson is passionate about his research and has a very personal reason for wanting to find a cure for cancer. During his first year of college, his 52-year-old mother was diagnosed with uterine cancer and died. He dedicated his life to finding a cure.

The two compounds developed in his lab hold promise in part because they efficiently disrupt the abnormally active STAT3 protein he said.

"We all have the STAT3 protein in our bodies, and under normal circumstances it causes no harm. But in breast cancer patients, the protein is abnormally active. It never shuts off."

When that happens, the protein goes into overdrive and is bent on supporting the proliferation of breast cancer cells. The protein even creates a network of blood vessels to feed the cancer cells, support their growth and eventually promote the spread of the cancer into the blood, bones and organs.

"Our compounds go after STAT3, stripping away its power," Turkson said.

Both compounds disrupt the bonding process that one STAT3 molecule goes through to connect with another in the body. If the STAT3 can't bond to stay abnormally-active, cancer cells can't develop. The network of blood vessels that formed to feed the cancer cells also shuts off.

Left without their source of food, the existing cancer cells die off. The body's immune system, which until now has been tricked by the abnormally active STAT3 into thinking the tumor cells are harmless, also recognizes that something is wrong. The immune system re-activates, recognizes any remaining cancer cells as harmful and destroys them.

Turkson worked with researchers at the H. Lee Moffitt Cancer Center and Research Institute, and the Beckman Research Institute and the Comprehensive Cancer Center of the City of Hope National Medical Center.

Turkson is a native of Ghana, West Africa. He completed his studies and obtained his honors B.S. degree in Biochemistry with Chemistry at the University of Ghana. He earned a Ph.D. in Pharmacology from the University of Alberta in Canada.

He completed post-doctoral fellow training in Molecular Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, where he served as an assistant professor before joining UCF's Burnett School of Biomedical Sciences in 2005.

While Turkson continues to look for partners to further his research, he's already working on a similar compound for pancreatic cancer.

In that case the compound would enhance the potency of another drug and use the body's immune system to make the effect more powerful.


'/>"/>

Contact: Zenaida Gonzalez Kotala
zkotala@mail.ucf.edu
407-823-6120
University of Central Florida
Source:Eurekalert  

Related biology news :

1. New microsensor measures volatile organic compounds in water and air on-site
2. Naturally-occurring apple compounds reduce risk of pancreatic cancer
3. UDs Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals
4. Green tea compounds beat OSA-related brain deficits
5. Natural compounds in cocoa tied to blood flow improvements for adults with type 2 diabetes
6. New study shows compounds from soy affect brain and reproductive development
7. Duke team finds compounds that prevent nerve damage
8. Discovery of natural compounds that could slow blood vessel growth
9. New $11 million center to speed production of new compounds for drug discovery
10. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
11. Scripps research scientists identify compounds for stem-cell production from adult cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
2 new compounds show promise for eliminating breast cancer tumors
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
Breaking Biology Technology: